<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199121</url>
  </required_header>
  <id_info>
    <org_study_id>TEAZE001</org_study_id>
    <nct_id>NCT00199121</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients</brief_title>
  <official_title>An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiviral effect and durability of antiviral
      response (HIV-1 RNA PCR) and safety of a triple NtRTI/NsRTI therapy in antiretroviral naive
      patients. Patients will receive TDF plus FTC plus AZT for at least 48 weeks. Further
      objectives are to evaluate resistance pathways in failing patients treated with TDF/FTC/AZT
      and to evaluate a treatment strategy of sparing PIs and NNRTIs for later treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  HIV-1 positive

          -  antiretroviral treatment naive

          -  one CD4 count &gt;200/ul within 14d prior to study drug administration

          -  one HIV-1 RNA PCR value &gt;5000 and &lt;100.000 cop/ml within 14d prior to study drug
             administration

          -  women of child bearing potential: negative serum pregnancy test within 14d of study

          -  ability to understand and provide written informed consent

          -  overall stable disease

          -  absence of clinical signs of lipodystrophy

        Exclusion Criteria:

          -  alcohol or illicit drug use

          -  malabsorption syndrome or other gastrointestinal dysfunction

          -  clinically relevant pancreatitis/hepatitis within the last 6 months

          -  receiving other investigational drugs

          -  abnormal hemoglobin, neutrophil, platelet, AST/ALT, pancreatic amylase, creatinine
             clearance, total bilirubine levels within 14d prior to study

          -  pregnancy/breast-feeding

          -  radiation therapy or cytotoxic chemotherapeutic agents within 30d of study

          -  prior antiretroviral therapy at any time, investigational antiretrovirals trial at any
             time, HIV vaccine within 90d prior to study

          -  immunomodulating agents

          -  serious medical condition (diabetes, congestive heart failure, cardiomyopathy, or
             other cardiac dysfunction)

          -  active diagnosis of AIDS (except for cutaneous Kaposi Sarcoma)

          -  foscarnet therapy or other agent with documented activity against HIV-1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Schlomo Staszewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the HIV Treatment &amp; Research Unit, Dept. of Internal Medicine II, Hospital of the Johann Wolfgang Goethe University Frankfurt/Main, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Schlomo Staszewski, MD</last_name>
    <phone>+49 69 6301</phone>
    <phone_ext>7680</phone_ext>
    <email>stasz@hivcenter.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carsten Rottmann, MD</last_name>
    <phone>+49 69 6301</phone>
    <phone_ext>7680</phone_ext>
    <email>carstenr@hivcenter.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HIV Treatment &amp; Research Unit, Dept. of Internal Medicine II, Hospital of the Johann Wolfgang Goethe University Frankfurt/Main</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel W. MÃ¼ller, MD</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>7680</phone_ext>
      <email>muellera@hivcenter.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 13, 2005</last_update_submitted>
  <last_update_submitted_qc>December 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2005</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

